Table 1: Basic information (per 1,000 LB) 42.4 (per 1,000 LB) 49.7 (per 1,000 LB) 215 (per 100,000 LB)

Transcription

1 EPI history EPI started in 978 EPI re-structured in March 000 DTP-HepB vaccine introduced in 007 DTP-Hib-HepB)vaccine introduced in 0 MR vaccine introduced in Feb 06 Second dose of MR introduced in Feb 06 HepB birth dose introduced in Feb 06 DPT/DT vaccine (booster dose) introduced in Feb 06 IPV introduced in Feb 06 topv to bopv switched on 8 April 06 Source: cmyp and EPI/MOH Disclaimer: The boundaries and names shown and the designations used on all the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Table : Basic information 07 Total population,6,407 Live births 33,88 Children < year 3,989 Children <5 years 64,73 Children <5 years 483,035 Pregnant women 37,70 WCBA (5-49 years) 33,387 Neonatal mortality rate Infant mortality rate Under-five mortality rate Maternal mortality ratio Division/Province/State/ Region.6 (per,000 LB) 4.4 (per,000 LB) 49.7 (per,000 LB) 5 (per 00,000 LB) Municipality 3 Postos/Sub-district 65 Sucos/Village 44 Population density (per sq. km) Population living in urban 33% areas Population using improved 7% drinking-water sources Population using improved 4% sanitation Total expenditure on health 3.% as % of GDP Births attended by skilled health personnel 56.7% Neonates protected at birth 8% against NT SEAR annual EPI reporting form, 07 WHO, Global Health Observatory (GHO) data int/gho/data accessed on 3 May 08 Table : Immunization schedule, 07 Vaccine BCG HepB DTP-Hib-HepB OPV IPV MR TT DT DTP Vitamin A Age of administration Birth Birth 6 weeks, 0 weeks and 4 weeks Birth, 6 weeks, 0 weeks and 4 weeks 4 weeks 9 months and 8 months Females 5 to 49 years (st pregnancy contact, + months, +6 months, + year, + year 6 years 8 months Source: WHO/UNICEF JRF, months (with 6 months interval) Table 3: Immunization system highlights cmyp for immunization NTAGI Spending on vaccines financed by the government Spending on routine immunization programme financed by the government Updated micro-plans that include activities to improve immunization coverage National policy for health care waste management including waste from immunization activities National system to monitor AEFI Most recent EPI CES fully functional 74% 3% 3 districts (00%) in place in place EPI CES Dili municipality and other municipalities 05 >80% coverage for DTP-Hib-HepB3 3 districts (00%) >90% coverage for MCV districts (84%) >0% drop-out rate for DTP-Hib- HepB to DTP-Hib-HepB3 district (8%) Source: WHO/UNICEF JRF 07 Figure : National immunization coverage, BCG DTP OPV MCV Source: WHO and UNICEF estimates of national immunization coverage, July 08 World Health Organization SEARO/FGL/IVD 3 July 08

2 Figure : DTP3 coverage, diphtheria and pertussis cases, Figure 3: TT+ coverage and NT cases, WHO and UNICEF estimates of national immunization coverage, July 08 WHO vaccine-preventable diseases: monitoring system 08 Country official estimates, WHO vaccine-preventable diseases: monitoring system 08 DTP-Hib-HepB3 coverage by district Figure 4: 06 Figure 5: 07 Source: SEAR annual EPI reporting form, 06 (administrative data) Source: SEAR annual EPI reporting form, 07 (administrative data) <70% 70% - 79% 80% - 89% >90% Table 4: Reported cases of vaccine preventable diseases, 0-07 Year Polio Diphtheria Pertussis NT (% of all tetanus) Measles Rubella Mumps JE CRS (40%) (9%) 4 0 ND 5 ND ND (00%) Source: WHO/UNICEF JRF (multiple years) ND=No data

3 Table 5: AFP surveillance performance indicators, 0-07 Indicator AFP cases Wild poliovirus confirmed cases Compatible cases Non-polio AFP rate Adequate stool specimen collection percentage 40% 0% 67% 0 50% 33% Total stool samples collected % NPEV isolation % Timeliness of primary result reported Number of discarded AFP cases per 00,000 children under 5 years of age. Percent with specimens, 4 hours apart and within 4 days of paralysis onset. 3 Result reported within 4 days of sample received at laboratory. Non-polio AFP rate by district Adequate stool specimen collection % by district Figure 6: 06 Figure 8: 06 Figure 7: 07 Figure 9: 07 < -.99 > No non-polio AFP case <60% 60% - 79% >80% No AFP case Table 6: OPV SIAs Year Antigen Geographic coverage Target age Target population Coverage (%) Round Round Round Round 005 OPV NID <5 years 77, * OPV NID <5 years 5, Source: WHO/UNICEF JRF (multiple years) * During MR vaccination campaign.

4 Figure 0: MCV & MCV coverage and measles, rubella cases, WHO and UNICEF estimates of national immunization coverage, July 08 WHO vaccine-preventable diseases: monitoring system 08 MCV coverage by district MCV coverage by district Figure : 06 Figure 3: 06 Source: SEAR annual EPI reporting form, 06 (administrative data) Source: SEAR annual EPI reporting form, 06 (administrative data) Figure : 07 Figure 4: 07 Source: SEAR annual EPI reporting form, 07 (administrative data) Source: SEAR annual EPI reporting form, 07 (administrative data) <80% 80% - 89% 90% - 94% >95% Table 7: MCV SIAs Year Antigen Geographic Coverage Target group Target Coverage 003 M nationwide 9 to 59 months 8, M nationwide 6 months to 4 years 390, M nationwide 9 to 59 months 67, M nationwide 6 months to 4 years 05 MR nationwide 6 months to 4 years Source: WHO/UNICEF JRF (multiple years) 494, ,83 97 Figure 5: Sub-national risk assessmentmeasles and rubella Very High Risk High Risk Medium Low Not Available World Health Organization SEARO/FGL/IVD 3 July 08

5 Figure 6: Immunity against measles - immunity profile by age in 07* *Modeled using MSP tool ver Figure 7: Sporadic and outbreak associated measles cases* by month 0-07 *Includes laboratory confirmed and epidemiologically linked cases Source: SEAR Monthly VPD reports Figure 8: Immunization status of confirmed (laboratory and Epi linked) measles outbreak associated cases, by age, 0-07 Source: SEAR annual EPI reporting form (multiple years)

6 Table 8: Surveillance performance indicator for measles and rubella, 0-07 Case classification (number) Indicators Year No. of Suspected Measles Lab-confirmed Measles Epi-Linked Clinically-confirmed Rubella Lab-confirmed Epi-Linked Discarded non-measles non-rubella cases Annual incidence of confirmed Measles cases per million total population Annual incidence of confirmed Rubella cases per million total population Proportion of all suspected measles and rubella cases that have had an adequate investigation initiated within 48 hours of notification Discarded non-measles non-rubella incidence per 00,000 total population Proportion of districts reporting at least two discarded non-measles non-rubella cases per 00,000 total population Proportion of sub-national surveillance units reporting to the national level on time Target 80% 80% 80% ND ND 00 Source: SEAR Annual EPI Reporting Form (multiple years) ND=No data Table 9: Performance of laboratory surveillance, 0-07 Year Serum specimen collected from suspected measles cases Serum specimen received in laboratory within 5 days of collection Specimen positive for measles IgM Specimen positive for rubella IgM % Results within 4 days of receipt % positive cases tested for viral detection Genotypes detected No (%) No (%) No. % No. % Measles Rubella 0 3 (46%) 3 (00%) (5%) (00%) (9%) 43 (00%) (7%) 34 (00%) (90%) 9 (00%) (99%) 6 (00%) Source: SEAR Annual EPI Reporting Form (multiple years) ND=No data Figure 9: Network of WHO supported surveillance medical officers and laboratories National Health Laboratory, Dili - National measles and rubella laboratory - National Japanese encephalitis laboratory For contact or feedback: Expanded Program on Immunization Ministry of Health, Dilli, Timor Leste Tel: , Fax: mmausiry@gmail.com, Immunization and Vaccine Development (IVD) WHO-SEARO, IP Estate, MG Marg, New Delhi 000, India Tel: , Fax: SearEpidata@who.int,